1
|
Gelbart B, McSharry B, Delzoppo C, Erickson S, Lee K, Butt W, Rea M, Wang X, Beca J, Kazemi A, Shann F. Pragmatic Randomized Trial of Corticosteroids and Inhaled Epinephrine for Bronchiolitis in Children in Intensive Care. J Pediatr 2022; 244:17-23.e1. [PMID: 35093318 DOI: 10.1016/j.jpeds.2022.01.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 12/22/2021] [Accepted: 01/18/2022] [Indexed: 10/19/2022]
Abstract
OBJECTIVE To determine whether the combination of systemic corticosteroids and nebulized epinephrine, compared with standard care, reduces the duration of positive pressure support in children with bronchiolitis admitted to intensive care. STUDY DESIGN We performed a pragmatic, multicenter, open-label, randomized trial between July 2013 and November 2019 in children younger than 18 months old with a clinical diagnosis of bronchiolitis. The intervention group received the equivalent of 13 mg/kg prednisolone over 3 days, then 1 mg/kg daily for 3 days, plus 0.05 mL/kg of nebulized 1% epinephrine made up to 6 ml with 0.9% saline via jet nebulizer and mask using oxygen at 12 l/min every 30 minutes for 5 doses, then 1-4 hourly for 3 days, then as required for 3 days. The primary outcome was clinician-managed duration of positive pressure support in intensive care defined as high-flow nasal-prong oxygen, nasopharyngeal continuous positive airway pressure, or mechanical ventilation. RESULTS In total, 210 children received positive pressure support. In the corticosteroid-epinephrine group, 107 children received positive pressure support for a geometric mean of 26 (95% CI, 22-32) hours compared with 40 (95% CI 34-47) hours in 103 controls, adjusted ratio 0.66 (95% CI 0.51-0.84), P = .001. In the intervention group, 41 (38%) children experienced at least 1 adverse event, compared with 39 (38%) in the control group. CONCLUSIONS In children with severe bronchiolitis, the duration of clinician-managed pressure support was reduced by regular treatment with systemic corticosteroids and inhaled epinephrine compared with standard care. CLINICAL TRIAL REGISTRATION Australian Clinical Trials Research Network: ACTRN12613000316707.
Collapse
Affiliation(s)
- Ben Gelbart
- Royal Children's Hospital Paediatric Intensive Care Unit, Melbourne, Australia; Department of Critical Care, University of Melbourne, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia.
| | - Brent McSharry
- Paediatric Intensive Care Unit, Starship Children's Hospital, Auckland, Australia
| | - Carmel Delzoppo
- Royal Children's Hospital Paediatric Intensive Care Unit, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia
| | - Simon Erickson
- Paediatric Critical Care Unit, Perth Children's Hospital, Perth, Australia
| | - Katherine Lee
- Department of Paediatrics, University of Melbourne, Melbourne, Australia; Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia
| | - Warwick Butt
- Royal Children's Hospital Paediatric Intensive Care Unit, Melbourne, Australia; Department of Critical Care, University of Melbourne, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia
| | - Miriam Rea
- Paediatric Intensive Care Unit, Starship Children's Hospital, Auckland, Australia
| | - Xiaofang Wang
- Department of Paediatrics, University of Melbourne, Melbourne, Australia; Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia
| | - John Beca
- Paediatric Intensive Care Unit, Starship Children's Hospital, Auckland, Australia
| | - Alex Kazemi
- Intensive Care Unit, Middlemore Hospital, Auckland, Australia
| | - Frank Shann
- Royal Children's Hospital Paediatric Intensive Care Unit, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Melbourne, Australia
| |
Collapse
|
2
|
Rosala-Hallas A, Jones AP, Williamson PR, Bedson E, Compton V, Fernandes RM, Lacy D, Lyttle MD, Peak M, Thorburn K, Woolfall K, Van Miert C, McNamara PS. Which outcomes should be used in future bronchiolitis trials? Developing a bronchiolitis core outcome set using a systematic review, Delphi survey and a consensus workshop. BMJ Open 2022; 12:e052943. [PMID: 35264343 PMCID: PMC8915376 DOI: 10.1136/bmjopen-2021-052943] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
OBJECTIVES The objective of this study was to develop a core outcome set (COS) for use in future clinical trials in bronchiolitis. We wanted to find out which outcomes are important to healthcare professionals (HCPs) and to parents and which outcomes should be prioritised for use in future clinical trials. DESIGN AND SETTING The study used a systematic review, workshops and interviews, a Delphi survey and a final consensus workshop. RESULTS Thirteen parents and 45 HCPs took part in 5 workshops; 15 other parents were also separately interviewed. Fifty-six items were identified from the systematic review, workshops and interviews. Rounds one and two of the Delphi survey involved 299 and 194 participants, respectively. Sixteen outcomes met the criteria for inclusion within the COS. The consensus meeting was attended by 10 participants, with representation from all three stakeholder groups. Nine outcomes were added, totalling 25 outcomes to be included in the COS. CONCLUSION We have developed the first parent and HCP consensus on a COS for bronchiolitis in a hospital setting. The use of this COS will ensure outcomes in future bronchiolitis trials are important and relevant, and will enable the trial results to be compared and combined. TRIAL REGISTRATION NUMBER ISRCTN75766048.
Collapse
Affiliation(s)
- A Rosala-Hallas
- Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, Merseyside, UK
| | - Ashley P Jones
- Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, Merseyside, UK
| | - Paula R Williamson
- Health Data Science, Institute of Population Health, University of Liverpool, Liverpool, UK
| | - Emma Bedson
- Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, Merseyside, UK
| | - Vanessa Compton
- Paediatric Intensive Care Unit, Alder Hey Children's NHS Foundation Trust, Liverpool, Merseyside, UK
| | - Ricardo M Fernandes
- Department of Pediatrics, Santa Maria Hospital, Lisbon Academic Medical Centre, Lisbon, Portugal
- Clinical Pharmacology and Therapeutics, Faculty of Medicine, Instituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal
| | - David Lacy
- Department of Paediatrics, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, Merseyside, UK
| | - Mark David Lyttle
- Emergency Department, Bristol Royal Hospital for Children, Bristol, UK
- Faculty of Health and Applied Science, University of the West of England, Bristol, UK
| | - Matthew Peak
- Clinical Research Division, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Kentigern Thorburn
- Paediatric Intensive Care Unit, Alder Hey Children's NHS Foundation Trust, Liverpool, Merseyside, UK
| | - Kerry Woolfall
- Institute of Population, Health and Society, University of Liverpool, Liverpool, Merseyside, UK
| | - Clare Van Miert
- School of Nursing and Allied Health, Liverpool John Moores University, Liverpool, Merseyside, UK
| | - Paul S McNamara
- Department of Child Health (University of Liverpool), Institute in the Park, Alder Hey Children's Hospital, Liverpool, Merseyside, UK
| |
Collapse
|
3
|
Song Y, Li R. Effect of budesonide combined with salbutamol nebulization on pulmonary function and serum immune factors in children with bronchiolitis. Am J Transl Res 2021; 13:8158-8164. [PMID: 34377300 PMCID: PMC8340181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Accepted: 08/04/2020] [Indexed: 06/13/2023]
Abstract
OBJECTIVE This study set out to investigate the effect of budesonide combined with salbutamol nebulization on pulmonary function and serum immune factors in children with bronchiolitis. METHODS A total of 127 children with bronchiolitis who were treated in our hospital were collected. Among them, 59 were treated with conventional bronchiolitis and were included in the control group (CG), and 68 were treated by budesonide combined with salbutamol inhalation in addition to the conventional treatment that were included in the research group (RG). The clinical efficacy, disappearance time of cough, pulmonary rales, wheezing and dyspnea, hospitalization time, adverse reactions, lung function and serum immune factors of the two groups were compared. RESULTS Compared with before treatment, cough, pulmonary rales, wheezing and dyspnea of children in both groups were improved after treatment. Compared with the CG, the disappearance time of cough, pulmonary rales, wheezing and dyspnea in the RG was shortened, the hospitalization time and adverse reactions reduced, and the total effective rate increased. The tidal volume, peak-to-peak time ratio (tPTEF/tE) and peak-to-peak volume ratio (VPTEF/VE) of the RG were dramatically better than those of the CG, and the levels of IgG, IgM and IgA were better than those of the CG. CONCLUSION Budesonide combined with salbutamol nebulization is beneficial to improve the pulmonary function and serum immune factors in children with bronchiolitis.
Collapse
Affiliation(s)
- Youbiao Song
- Department of Pediatrics, Taihe County People's Hospital Fuyang 236605, Anhui Province, China
| | - Ruihua Li
- Department of Pediatrics, Taihe County People's Hospital Fuyang 236605, Anhui Province, China
| |
Collapse
|
4
|
Rosala-Hallas A, Jones AP, Bedson E, Compton V, Fernandes RM, Lacy D, Lyttle MD, Peak M, Thorburn K, van Miert C, Woolfall K, McNamara PS. National survey of feasibility of NIV trials for management of children with bronchiolitis. BMJ Paediatr Open 2020; 4:e000780. [PMID: 33134562 PMCID: PMC7592239 DOI: 10.1136/bmjpo-2020-000780] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2020] [Revised: 08/07/2020] [Accepted: 08/25/2020] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Bronchiolitis is a major cause of admission to hospital in children. Non-invasive ventilation (NIV) support with continuous positive airway pressure (CPAP) or high-flow nasal cannula (HFNC) oxygen is routinely used for infants in the UK with bronchiolitis. OBJECTIVE To establish UK paediatric practice regarding management of bronchiolitis, and to explore issues pertinent to the design of a potential future randomised controlled trial of NIV. DESIGN Screening logs were completed in hospitals in England capturing information on paediatric bronchiolitis admissions. An online national survey of clinical practice was disseminated to healthcare professionals (HCPs) across the UK to ascertain current management strategies. RESULTS Screening logs captured data on 393 infants from 8 hospitals. Reasons for admission were most commonly respiratory distress and/or poor fluid intake. Oxygen was administered for 54% of admissions. Respiratory (CPAP and HFNC) and non-respiratory support administered varied considerably. The national survey was completed by 111 HCPs from 76 hospitals. Data were obtained on criteria used to commence and wean NIV, responsibilities for altering NIV settings, minimum training requirements for staff managing a child on NIV, and numbers of trained staff. Most centres were interested in and capable of running a trial of NIV, even out of normal office hours. CONCLUSIONS Respiratory and non-respiratory management of bronchiolitis in UK centres varies widely. A trial of HFNC oxygen therapy in this group of patients is feasible and HCPs would be willing to randomise patients into such a trial. Future work should focus on defining trial eligibility criteria.
Collapse
Affiliation(s)
- Anna Rosala-Hallas
- Liverpool Clinical Trials Centre, Department of Biostatistics, University of Liverpool (a member of Liverpool Health Partners), Liverpool, UK
| | - Ashley P Jones
- Liverpool Clinical Trials Centre, Department of Biostatistics, University of Liverpool (a member of Liverpool Health Partners), Liverpool, UK
| | - Emma Bedson
- Liverpool Clinical Trials Centre, Department of Biostatistics, University of Liverpool (a member of Liverpool Health Partners), Liverpool, UK
| | - Vanessa Compton
- Paediatric Intensive Care Unit, Alder Hey Children’s NHS Foundation Trust, Liverpool, Merseyside, UK
| | - Ricardo M Fernandes
- Instituto de Medicina Molecular, Clinical Pharmacology and Therapeutics, Faculty of Medicine, Universidade de Lisboa, Lisbon, Portugal
- Department of Paediatrics, Lisbon Academic Medical Centre, Hospital de Santa Maria, Lisbon, Portugal
| | - David Lacy
- Department of Paediatrics, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK
| | - Mark D Lyttle
- Emergency Department, Bristol Royal Hospital for Children, Bristol, UK
- Faculty of Health and Applied Sciences, University of the West of England, Bristol, Avon, UK
| | - Matthew Peak
- Clinical Research Division, Alder Hey Children's NHS Foundation Trust, Liverpool, Merseyside, UK
| | - Kent Thorburn
- Paediatric Intensive Care Unit, Alder Hey Children’s NHS Foundation Trust, Liverpool, Merseyside, UK
| | - Clare van Miert
- Paediatric Intensive Care Unit, Alder Hey Children’s NHS Foundation Trust, Liverpool, Merseyside, UK
- School of Nursing and Allied Health, Liverpool John Moores University, Liverpool, Merseyside, UK
| | - Kerry Woolfall
- Institute of Population Health and Society, University of Liverpool, Liverpool, Merseyside, UK
| | - Paul S McNamara
- Institute of Child Health, University of Liverpool, Liverpool, Merseyside, UK
| |
Collapse
|
5
|
Mammas IN, Drysdale SB, Rath B, Theodoridou M, Papaioannou G, Papatheodoropoulou A, Koutsounaki E, Koutsaftiki C, Kozanidou E, Achtsidis V, Korovessi P, Chrousos GP, Spandidos DA. Update on current views and advances on RSV infection (Review). Int J Mol Med 2020; 46:509-520. [PMID: 32626981 PMCID: PMC7307844 DOI: 10.3892/ijmm.2020.4641] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 06/15/2020] [Indexed: 12/11/2022] Open
Abstract
Respiratory syncytial virus (RSV) infection represents an excellent paradigm of precision medicine in modern paediatrics and several clinical trials are currently performed in the prevention and management of RSV infection. A new taxonomic terminology for RSV was recently adopted, while the diagnostic and omics techniques have revealed new modalities in the early identification of RSV infections and for better understanding of the disease pathogenesis. Coordinated clinical and research efforts constitute an important step in limiting RSV global predominance, improving epidemiological surveillance, and advancing neonatal and paediatric care. This review article presents the key messages of the plenary lectures, oral presentations and posters of the '5th workshop on paediatric virology' (Sparta, Greece, 12th October 2019) organized by the Paediatric Virology Study Group, focusing on recent advances in the epidemiology, pathogenesis, diagnosis, prognosis, clinical management and prevention of RSV infection in childhood.
Collapse
Affiliation(s)
- Ioannis N Mammas
- Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece
| | | | - Barbara Rath
- Vienna Vaccine Safety Initiative, D‑10437 Berlin, Germany
| | - Maria Theodoridou
- First Department of Paediatrics, University of Athens School of Medicine, 11527 Athens, Greece
| | - Georgia Papaioannou
- Department of Paediatric Radiology, 'Mitera' Children's Hospital, 15123 Athens, Greece
| | | | - Eirini Koutsounaki
- Neonatal Department, 'Alexandra' Maternity Hospital, 15123 Athens, Greece
| | - Chryssie Koutsaftiki
- Paediatric Intensive Care Unit (PICU), 'Penteli' Children's Hospital, 15236 Penteli, Greece
| | - Eleftheria Kozanidou
- 2nd Department of Internal Medicine, 'St Panteleimon' General Hospital of Nikaia, 18454 Piraeus, Greece
| | - Vassilis Achtsidis
- Department of Ophthalmology, Royal Cornwall Hospitals, Cornwall TR1 3LQ, UK
| | - Paraskevi Korovessi
- Department of Paediatrics, 'Penteli' Children's Hospital, 15236 Penteli, Greece
| | - George P Chrousos
- First Department of Paediatrics, University of Athens School of Medicine, 11527 Athens, Greece
| | - Demetrios A Spandidos
- Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece
| |
Collapse
|
6
|
Panciatici M, Fabre C, Tardieu S, Sauvaget E, Dequin M, Stremler-Le Bel N, Bosdure E, Dubus JC. Use of high-flow nasal cannula in infants with viral bronchiolitis outside pediatric intensive care units. Eur J Pediatr 2019; 178:1479-1484. [PMID: 31372745 DOI: 10.1007/s00431-019-03434-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/27/2019] [Revised: 06/30/2019] [Accepted: 07/16/2019] [Indexed: 10/26/2022]
Abstract
High-flow nasal cannula (HFNC) is frequently used in infants with acute viral bronchiolitis outside pediatric intensive care units (PICU). A structured questionnaire was sent out to pediatricians of all public French hospitals with pediatric emergency and/or general pediatric departments on their use of HFNC outside PICU (department using HFNC, number of available devices, monitoring, criteria for initiating or stopping HFNC, and personal comments on HFNC). Of the 166 eligible hospitals, 135 answered (96 general and 39 university hospitals; 81.3%), for a total of 217 answering pediatricians. Seventy-two hospitals (53.3%) used HFNC in acute bronchiolitis outside PICU, particularly, general hospitals (59.4% vs 38.5%), and mostly in pediatric general departments (75%). Continuous patient monitoring with a cardiorespiratory monitor was usual (n = 58, 80%). Nursing staff was responsible for 2.7 children on HFNC and checked vital signs 8.6 times per day. Criteria for HFNC initiation and withdrawal were not standardized. Pediatricians had a positive opinion of HFNC and were willing to extend its use to other diseases.Conclusion: Use of HFNC outside PICU in infants with acute bronchiolitis is now usual, but urgently requires guidelines. What is Known: • Acute viral bronchiolitis treatment is only supportive • High-flow nasal cannula (HFNC) is a respiratory support accumulating convincing clinical evidence in bronchiolitis • This latter treatment is usually proposed in pediatric intensive care unit (PICU) What is New: • HFNC are increasingly used outside PICU in bronchiolitis, particularly, in general hospitals and in pediatric general departments • Pediatricians are enthusiastic about this device, but validated criteria for initiation and withdrawal are lacking • Guidelines for the use of HFNC outside PICU are urgently required.
Collapse
Affiliation(s)
- Mélanie Panciatici
- Service de Médecine Infantile et Pneumologie pédiatrique, CHU Timone-Enfants, 264 rue Saint-Pierre, 13385, Marseille Cedex 5, France.
| | - Candice Fabre
- Service de Médecine Infantile et Pneumologie pédiatrique, CHU Timone-Enfants, 264 rue Saint-Pierre, 13385, Marseille Cedex 5, France
| | - Sophie Tardieu
- Service d'Evaluation médicale, Pôle de Santé publique, Hôpital de la Conception, Marseille, France
| | - Emilie Sauvaget
- Service de pédiatrie, Hôpital Saint-Joseph, Marseille, France
| | - Marion Dequin
- Service de Médecine Infantile et Pneumologie pédiatrique, CHU Timone-Enfants, 264 rue Saint-Pierre, 13385, Marseille Cedex 5, France
| | - Nathalie Stremler-Le Bel
- Service de Médecine Infantile et Pneumologie pédiatrique, CHU Timone-Enfants, 264 rue Saint-Pierre, 13385, Marseille Cedex 5, France
| | - Emmanuelle Bosdure
- Service de Médecine Infantile et Pneumologie pédiatrique, CHU Timone-Enfants, 264 rue Saint-Pierre, 13385, Marseille Cedex 5, France
| | - Jean-Christophe Dubus
- Service de Médecine Infantile et Pneumologie pédiatrique, CHU Timone-Enfants, 264 rue Saint-Pierre, 13385, Marseille Cedex 5, France.,IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, Aix Marseille Université, Marseille, France
| |
Collapse
|
7
|
de Benedictis FM. Treachery on the Rocks in the Pediatric Intensive Care Unit-Reply. JAMA Pediatr 2019; 173:699-700. [PMID: 31081859 DOI: 10.1001/jamapediatrics.2019.1191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|